Degarelix HY-16168A from MedChemExpress

Product Specs
ItemDegarelix
CompanyMedChemExpress
Price $108.00Supplier Page View Company Product Page
Catalog NumberHY-16168A
Size2 mg
ApplicationsBioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity99.94%
TypeChemical
Molecular Weight1632.26
FormulaC₈₂H₁₀₃ClN₁₈O₁₆
Research AreaEndocrinology; Cancer

Add to Compare List

MedChemExpress

1 Deer Park Drive, Suite F

MONMOUTH JUNCTION, NJ 08852

United States

Phone: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910

Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com

Company Profile

Website: medchemexpress.com

(1) Characteristics of tertiary lymphoid structures in prostate cancer and the impact of neoadjuvant therapy on their formation and maturationFrontiers in ImmunologyNovember 4, 2025Shengzhuo Liu, Yunfei Yu, Jing Zhou, Lucheng Yang, Xin Yan, Xiaoyang Liu, Kai Ma, Liangren Liu, Xianding Wang, Chengjian Zhao, et al.groups: vehicle control (0.9% saline), ADT group (degarelix, 0.625mg/mouse, every 28 days, s.c, MCE, HY-16168A; bicalutamide, every 3 days, intraperitoneal injection, MCE, HY-14249), immunotherapy group (PD-1 blockade,

(2) A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug CandidatesCellsApril 8, 2025Yonika A. Larasati, Gonzalo P. Solis, Alexey Koval, Christian Korff, Vladimir L. KatanaevMedChemExpress: nafamostat mesylate (HY-B0190A) and its analog sepimostat (HY-136299-S), degarelix (HY-16168A), aviptadil acetate (HY-P0012A), and oritavancin diphosphate (HY-B1831A). 3. Results 3.1. Mutations

(3) Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate CancerClinical cancer research : an official journal of the American Association for Cancer ResearchMay 15, 2023Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, et al.mice were treated with either degarelix (0.625 mg/mouse, sc, every 28-days, ADT group, MedchemExpress; HY16168A), copanlisib (14mg/kg, iv, every alternate day, Selleckchem; BAY 80–6946), PD-1 antibody (aPD-1, 200

(4) In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growthPloS oneJanuary 1, 2015Sakai M, Martinez-Arguelles DB, Patterson NH, Chaurand P, Papadopoulos V.

(5) An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancerOncoTargets and therapyJanuary 1, 2013Rick FG, Block NL, Schally AV.

(6) Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkeyDrug metabolism and disposition: the biological fate of chemicalsOctober 1, 2011Sonesson A, Koechling W, Stalewski J, Tankó LB, Rasmussen BB.

(7) Ti2C80 is more likely a titanium carbide endohedral metallofullerene (Ti2C2)@C78Chemical communications (Cambridge, England)September 21, 2005Tan K, Lu X.

(8) Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelixThe Journal of pharmacology and experimental therapeuticsApril 1, 2002Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL.

Be the First to Write a Review!

Degarelix from MedChemExpress

Description

MedChemExpress

Citations (8)

Reviews

Degarelix from MedChemExpress

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map